A US panel voted in favour of wider use of Abbott Laboratories’ rheumatoid arthritis drug, Humira. The drug is already approved for six other conditions and now it has been backed to treat ...

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly ...

Winter founded Cambridge Antibody Technology in 1989, which first discovered adalimumab using phage display technology as part of a development partnership with BASF Pharma. After Abbott bought ...

The fully human anti-TNF-α antibody adalimumab (Humira; Abbott) was approved by the FDA in 2007. This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody ...

The big drugmaker's 52 consecutive years of dividend increases (including when it was part of Abbott) qualify it as ... a fabulous pick by many investors. Humira, the company's top-selling drug ...

Abbott's biologics franchise consists of a single drug, adalimumab (Humira), the consensus sales of which account for 54% of its MRDP revenue of $14.9 billion in 2013E. Coupled with minor exposure ...

Since the company was spun out of Abbott Laboratories in 2013 ... to $58.1bn in 2022 was the success of its rheumatoid arthritis drug Humira. For 20 years, the treatment was shielded from ...